+49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population

Human Immunology

Volumn 71, Issue 1, 2010, Pages 83-87

  Gu, Xing ^a   Qi, Peng ^a   Zhou, Feiguo ^a   Ji, Qiang ^a   Wang, Hao ^b   Dou, Tonghai ^c   Zhao, Yunpeng ^a   Gao, Chunfang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

CTLA 4; HBV related HCC; SNP; Susceptibility

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTIGENS, CD; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX FACTORS;

EID: 71249084658     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.09.353     Document Type: Article

References (43)

1. Dariavach P., Mattei M.G., Golstein P., and Lefranc M.P. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 18 (1988) 1901-1905
2. Scheipers P., and Reiser H. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA 95 (1998) 10083-10088
3. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
4. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270 (1995) 985-988
5. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100 (2003) 4712-4717
6. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
7. Attia P., Phan G.Q., Maker A.V., Robinson M.R., Quezado M.M., Yang J.C., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053
8. Kwon E.D., Foster B.A., Hurwitz A.A., Madias C., Allison J.P., Greenberg N.M., et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 96 (1999) 15074-15079
9. Thompson R.H., Allison J.P., and Kwon E.D. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 24 (2006) 442-447
10. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
11. Cheng T.Y., Lin J.T., Chen L.T., Shun C.T., Wang H.P., Lin M.T., et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 24 (2006) 3483-3489
12. Ben Dhifallah I., Chelbi H., Braham A., Hamzaoui K., and Houman M.H. CTLA-4 +49 A/G polymorphism is associated with Behçet's disease in a Tunisian population. Tissue Antigens 73 (2009) 213-217
13. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., and DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165 (2000) 6606-6611
14. Barreto M., Santos E., Ferreira R., Fesel C., Fontes M.F., Pereira C., et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 12 (2004) 620-626
15. Lee Y.H., Harley J.B., and Nath S.K. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a metaanalysis. Hum Genet 116 (2005) 361-367
16. Zhernakova A., Eerligh P., Barrera P., Wesoly J.Z., Huizinga T.W., Roep B.O., et al. CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Hum Genet 118 (2005) 58-66
17. Nisticò L., Buzzetti R., Pritchard L.E., Van der Auwera B., Giovannini C., Bosi E., et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 5 (1996) 1075-1080
18. Zalloua P.A., Abchee A., Shbaklo H., Zreik T.G., Terwedow H., Halaby G., et al. Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene. Hum Immunol 65 (2004) 719-724
19. LaBerge G.S., Bennett D.C., Fain P.R., and Spritz R.A. PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. J Invest Dermatol 128 (2008) 1757-1762
20. Kelley J.M., Hughes L.B., Faggard J.D., Danila M.I., Crawford M.H., Edberg Y., et al. An African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans. PLoS Genet 5 (2009) e100042-e100044
21. Ghaderi A., Yeganeh F., Kalantari T., Talei A.R., Pezeshki A.M., Doroudchi M., et al. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 86 (2004) 1-7
22. Sun T., Zhou Y., Yang M., Hu Z., Tan W., Han X., et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 68 (2008) 7025-7034
23. Jiang Z., Feng X., Zhang W., Gao F., Ling Q., Zhou L., et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. Liver Int 27 (2009) 1202-1208
24. World Health Organization. Mortality database. WHO statistical information system. http://www.who.int/whosis/ Accessed July 2008.
25. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc 295 (2006) 65-73
26. Alegre M.L., Frauwirth K.A., and Thompson C.B. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1 (2001) 220-228
27. Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 13 (2007) 5238-5242
28. Carreno M., Bennett F., Chau T.A., Ling V., Luxenberg D., Jussif J., et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165 (2000) 1352-1356
29. Awata T., Kurihara S., Iitaka M., Takei S., Inoue I., Ishii C., et al. Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47 (1998) 128-129
30. Gough S.C., Walker L.S., and Sansom D.M. CTLA4 gene polymorphism and autoimmunity. Immunol Rev 204 (2005) 102-115
31. Wong Y.K., Chang K.W., Cheng C.Y., and Liu C.J. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 35 (2006) 51-54
32. Mäurer M., Loserth S., Kolb-Mäurer A., Ponath A., Wiese S., Kruse N., et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene (exon 1-49) alters T-cell activation. Immunogenetics 54 (2002) 1-8
33. Yung E., Cheng P.S., Fok T.F., and Wong G.W. CTLA-4 gene A-G polymorphism and childhood Graves' disease. Clin Endocrinol 56 (2002) 649-653
34. Fernández-Mestre M., Sánchez K., Balbás O., Gendzekhzadze K., Ogando V., Cabrera M., et al. Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum Immunol 70 (2009) 532-535
35. Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A., Vlahov D., et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 78 (2004) 11258-11262
36. Yee L.J., Perez K.A., Tang J., van Leeuwen D.J., and Kaslow R.A. Association of CTLA-4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 187 (2003) 1264-1271
37. Popper H., Gerber M.A., and Thung S.N. The relation of hepatocellular carcinoma to infection with hepatitis B and related viruses in man and animals. J Hepatol 2 (1982) 1S-9S
38. Beasley R.P., Hwang L.Y., Lin C.C., and Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 2 (1981) 1129-1133
39. Dickinson J.A., Wun Y.T., and Wong S.L. Modelling death rates for carriers of hepatitis B. Epidemiol Infect 128 (2002) 83-92
40. Shin H.D., Park B.L., Kim L.H., Jung J.H., Kim J.Y., Yoon J.H., et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 12 (2003) 901-906
41. Qi P., Chen Y.M., Wang H., Fang M., Ji Q., Zhao Y.P., et al. -509C > T polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol Immunother 58 (2009) 1433-1440
42. Kalra M., Mayes J., Assefa S., Kaul A.K., and Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol 14 (2008) 5945-5961
43. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124